Natpar for Hypoparathyroidism Gets Green Light in Europe Natpar for Hypoparathyroidism Gets Green Light in Europe
The first replacement hormone therapy for chronic hypoparathyroidism that cannot be treated with standard therapy of calcium and vitamin D, a rare disease, has passed the first hurdle for approval in the EU.International Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Calcium | Diabetes | Endocrinology | Hormonal Therapy | Hormones | Rare Diseases | Vitamins